Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01HDP
|
|||
| Former ID |
DCL000230
|
|||
| Drug Name |
SLV 306
|
|||
| Synonyms |
Daglutril; SLV 306; SLV-306; SLV306; UNII-KKV299446X; 182821-27-8; KKV299446X; ((3S)-3-{1-((2R)-2-Ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxamido}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)acetic acid; Daglutril [INN]; 2-[(3S)-3-[[1-[(2R)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid; 1H-1-Benzazepine-1-acetic acid, 3-(((1-(2-(ethoxycarbonyl)-4-phenylbutyl)cyclopentyl)carbonyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (S-(R*,S*))-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute decompensated heart failure [ICD-11: BD1Z; ICD-10: I50, I50.9] | Phase 2 | [1], [2] | |
| Company |
Solvay Pharma
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H38N2O6
|
|||
| Canonical SMILES |
CCOC(=O)C(CCC1=CC=CC=C1)CC2(CCCC2)C(=O)NC3CCC4=CC=CC=C4N(C3=O)CC(=O)O
|
|||
| InChI |
1S/C31H38N2O6/c1-2-39-29(37)24(15-14-22-10-4-3-5-11-22)20-31(18-8-9-19-31)30(38)32-25-17-16-23-12-6-7-13-26(23)33(28(25)36)21-27(34)35/h3-7,10-13,24-25H,2,8-9,14-21H2,1H3,(H,32,38)(H,34,35)/t24-,25+/m1/s1
|
|||
| InChIKey |
XMQODGUTLZXUGZ-RPBOFIJWSA-N
|
|||
| CAS Number |
CAS 182821-27-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Endothelin-converting enzyme (ECE) | Target Info | Modulator | [3] |
| Neutral endopeptidase (MME) | Target Info | Modulator | [3], [4] | |
| KEGG Pathway | Renin-angiotensin system | |||
| Hematopoietic cell lineage | ||||
| Protein digestion and absorption | ||||
| Alzheimer's disease | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | Metabolism of Angiotensinogen to Angiotensins | |||
| Primary Focal Segmental Glomerulosclerosis FSGS | ||||
| Alzheimers Disease | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6506). | |||
| REF 2 | ClinicalTrials.gov (NCT00160225) Study to Evaluate the Efficacy and Safety of Daglutril Compared to Placebo on Top of Losartan in Type 2 Diabetics With Overt Nephropathy and Well Controlled Hypertension. U.S. National Institutes of Health. | |||
| REF 3 | The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. Life Sci. 2012 Oct 15;91(13-14):743-8. | |||
| REF 4 | Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol. 2004 Jul 15;94(2):237-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.